Radioimmunodetection of Cancer

Kim, E. Edmund

doi:10.1007/978-1-4757-3505-5_7

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus far, these antibodies have been directed toward carcinoembryonic (CEA) antigen, glycoprotein-72, a cell surface antigen of pancarcinoma, and a prostate cancer antigen, to name a few. [48][49][50][51] Initial work with whole, intact ]FDG-PET imaging before and after chemotherapy in two patients with osteosarcoma in the distal femur. The first patient (A,B) demonstrated high FDG uptake before (A) and after (B) chemotherapy, resulting in a low prechemotherapy standard uptake value (SUV1): postchemotherapy SUV (SUV2) ratio.…”

Section: Cancer Imagingmentioning

confidence: 99%

Molecular Imaging of Musculoskeletal Diseases

Biswal

2003

Semin Musculoskelet Radiol

View full text Add to dashboard Cite

Chronic musculoskeletal diseases such as arthritis, malignancy, chronic injury/ inflammation, and chronic musculoskeletal pain often pose challenges for current clinical imaging modalities. There is hope that a growing field, referred to as "molecular imaging," will shed new light on these chronic phenomenon as it aims to noninvasively detect special molecular and physiologic effects such as metabolism rate, specific proteins, cell death, and particular gene-related events. Molecular imaging represents recent advances in imaging technology, engineering, chemistry, molecular biology, and genetics that have coalesced into a multidisciplinary and multimodality effort. Molecular probes are currently being developed not only in radionuclide-based techniques but also in magnetic resonance imaging, magnetic resonance spectroscopy, ultrasound, and the emerging field of optical imaging. Furthermore, molecular imagers are fueling the development of novel molecular therapies and gene therapy, as tracking these efforts in living subjects is now possible with molecular imaging protocols.

show abstract

Section: Cancer Imagingmentioning

confidence: 99%

Molecular Imaging of Musculoskeletal Diseases

Biswal

2003

Semin Musculoskelet Radiol

View full text Add to dashboard Cite

show abstract

“…PAI-2 also contains a so-called CD-loop, a sequence of 33 amino acids between the C and D α-helices that may be involved in various intracellular functions [22], but is not required for uPA inhibition [23]. Removal of the CD-loop to generate the shortened form of PAI-2 (∆CDloop PAI-2; ~44 KDa) is simpler to express and purify recombinantly, retains full uPA inhibitory characteristics [23] and may potentially exhibit a more favourable PK profile -6 -for imaging as is typically seen when the size of a targeting protein is decreased [24]. The circulation of proteins can also be modified by PEGylation, via conjugation of one or more polyethylene glycol (PEG) units [25].…”

Section: Introductionmentioning

confidence: 99%

Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms

Ranson

Berghofer

Vine

et al. 2012

Nuclear Medicine and Biology

View full text Add to dashboard Cite

The different labelling methods gave distinct PAI-2 BD and tumour uptake profiles, with radioiodination resulting in the best non-tumour organ clearance profiles. Preliminary analyses with short branched-chain PEGylated (123)I-Bn-PAI-2 ΔCD-loop suggest that further investigations with other PEGylation reagents are required to optimise this approach for tumour imaging. These findings impact on the use of PAI-2 for drug delivery and/or diagnostic development.

show abstract